- IN BRIEF
Targeting CDK12 to treat DM1
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 19, 388 (2020)
doi: https://doi.org/10.1038/d41573-020-00086-0
References
Ketley, A. et al. CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Sci. Transl. Med. 12, eaaz2415 (2020)